PROGNOSTIC MARKERS OF ACUTE MYELOID LEUKEMIA SURVIVAL

摘要

Methods and kits for the diagnosis and prognosis of acute myeloid leukemia (AML) are described. These methods and kits are based on the assessment of the level of expression of the gene High Mobility Group AT-hook 2 (HMGA2), and optionally of the level of expression of at least one additional prognostic marker gene such as PRKC Apoptosis WT1 Regulator (PAWR), in a biological sample from an AML patient. High levels of expression of HMGA2 and PAWR in the sample are associated with poor disease prognosis, for example low probability of survival and/or increased risk of relapse, in AML patients, including in intermediate-risk AML patients. Methods and kits for the diagnosis of AMLs with TP53 mutations based on genes differentially expressed in AMLs with TP53 mutations relative to other AMLs also described.